Complete Guide to rucaparib ok model Pharmacokinetics
Overview
rucaparib ok model is a PARP Inhibitor used in the Oncology therapeutic area. It is indicated for Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC). Interactive population pharmacokinetic simulator for rucaparib (Rubraca), an oral PARP inhibitor approved for ovarian cancer and mCRPC. Two-compartment model with covariate effects of creatinine clearance and albumin on clearance. Based on Green et al. Cancer Chemother Pharmacol (2022).
Mechanism of Action
rucaparib ok model exerts its pharmacological effect by targeting PARP (poly ADP-ribose polymerase). As a PARP Inhibitor, it modulates this target to achieve therapeutic efficacy in Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC). Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK (2-compartment) models for rucaparib ok model:
| Parameter | Value |
|---|---|
| Ka | 1.49 h⁻¹ |
| Q F | 4.42 L/h |
| CL F | 17.2 L/h |
| Vc F | 114 L |
| Vp F | 52.6 L |
| t half | ~17 h |
| covariates | Creatinine clearance on CL, albumin on CL, body weight |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
rucaparib ok model is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), understanding the pharmacokinetics of rucaparib ok model is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect rucaparib ok model pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive rucaparib ok model PK Simulator
Explore rucaparib ok model pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of rucaparib ok model?
The elimination half-life of rucaparib ok model depends on patient-specific factors. Based on published models, the typical half-life is approximately ~17 h.
How is rucaparib ok model administered?
rucaparib ok model is administered via the Oral route. It is indicated for Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC). As a PARP Inhibitor, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of rucaparib ok model?
Key pharmacokinetic parameters for rucaparib ok model include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate rucaparib ok model dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive rucaparib ok model PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.